$BRGX Cashflow Statement | Understand Stock

$BRGX

$0.01 -$0.00 (31.25%) Close

$BRGX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022
Net loss
Amortization expense
Investment in Chill N Out Cryotherapy – related party
Common stock issued for services
Common stock issued for expenses– related party
Loss on conversion of debt – related party
Depreciation and amortization
Amortization of debt discounts
Fair value of options issued to officers and directors for services
Impairment
Fair value of common shares issued for services
Interest capitalized to debt balance
Fair value of common shares issued as loan incentives
Fair value of warrants issued for refunds
Accounts receivable
Inventories
Prepaid expenses and other assets
Accounts payable
Accounts payable - related parties
Accrued expenses and other liabilities
Accrued interest - related parties
Deferred Revenue
Net cash provided by (used in) operating activities
Purchases of property and equipment
Purchases of Intangibles
Advance on acquisition
Cash acquired in DocSun transaction
Net cash used in investing activities
Proceeds from long term debt
Note and loan payments
Note and loan payments - related parties
Proceeds from loans payable – related party
Increase in note and loan balances
Increase in note and loan balances - related parties
Proceeds from the issuance of common stock
Net cash provided by financing activities
Net Change in Cash
NET EFFECT OF EXCHANGE RATE FLUCTUATIONS
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS, BEGINNING BALANCE
CASH AND CASH EQUIVALENTS, ENDING BALANCE
CASH PAID FOR:
Interest
Income taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Unrealized loss on available-for-sale securities
Common stock issued debt – related party
Fair value of common stock issued for intangible property and equipment in the acquisition of DocSun Biomedical Holdings, Inc.
Fair value of common stock issued upon acquisition of intangible property and goodwill in the merger with Findit, Inc.
Fair value of common stock and warrants issued for refunds offset to deferred revenue
Fair value of common stock and warrants issued for loan fees offset to loan discounts
Reclass of deposits to intangibles
Fair value of common stock and warrants issued for refunds offset to return reserve
Liability incurred upon acquisition of intangible

Comments